F-18 FLT shows promise for antiangiogenic therapy assessment

08/8/2013 | MolecularImaging.net

A study in the Journal of Nuclear Medicine evaluated three F-18 labeled PET tracers with axitinib for assessment of antiangiogenic therapy response. Researchers conducted PET scans in mice with heterogeneous glioma and breast ductal carcinoma using PET tracers F-18 FDG, F-18 FLT and F-18 FtRGD, finding F-18 FLT allowed overall earlier detection of the therapeutic response, but each agent had different strengths. "These data suggest that differences in tumor biology may be critical for individual patient management and the choice of radiopharmaceutical agents for the noninvasive monitoring of therapy efficacy," the authors wrote.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD